No. 1 South Carolina experiences rare sting of lossThousands of Syrians celebrate in central Damascus during first Friday prayers since Assad's fallAVITA Medical Announces FDA Approval of RECELL GO mini, Optimizing Treatment for Smaller Wounds
No. 1 South Carolina experiences rare sting of loss
This past summer, I reviewed , but now I have the AMD Ryzen AI version in house. It should make for an interesting comparison, given the stellar battery life and terrific performance I saw previously. Sign up for our new free newsletter to get three time-saving tips each Friday — get free copies of Paul Thurrott's Windows 11 and Windows 10 Field Guides (normally $9.99) as a special welcome gift! . This is a 14-inch ThinkPad T14s with an AMD Ryzen AI 7 PRO 360 processor and Radeon 880M graphics, 32 GB of RAM, and a 1 TB NVMe SSD. The display is Full HD+ (1920 x 1200) with a 16:10 aspect ratio, and I’m guessing it’s the same entry-level and low-power IPS panel the previous T14s came with. Expansion looks identical, too. There are two Thunderbolt 4/USB4 Type-C ports and a full-sized HDMI port (plus a combo microphone/headphone jack) on the left, and then two full-sized USB 3 Type-A ports on the right, plus a Kensington nano security slot. Wi-Fi 7 and Bluetooth 5.3 are available for connectivity, as with the Snapdragon version. There are two top-firing speakers, with grills on either side of the keyboard, that support Dolby Atmos immersive sound. And that keyboard is full-sized and backlit, and appears to be Lenovo’s most modern version, with island-style scalloped keys, correct Ctrl/Fn placement, and an overloaded arrow key area with physical PgUp and PgDn keys. The T14s features Lenovo’s vaunted TrackPoint pointing system, with the nubbin in the center of the keyboard and dedicated keys, plus a small-ish (for these days) mechanical touchpad. The round power button to the upper right of the keyboard doubles as a Windows Hello Enhanced Sign-In Security (ESS) fingerprint reader, and there’s a Windows Hello ESS compatible webcam too, of course: This is, or soon will be, a full-featured Copilot+ PC. All the useful ThinkPad bits are present and accounted for, from the light-up red dot on the “i” in the ThinkPad logo on the exterior display lid to the subtle Lenovo branding. It comes in one color, Eclipse Black, as one should expect from a ThinkPad. It’s light for a 14-inch laptop, at just 2.86 pounds. Power comes via a standard 65-watt Lenovo USB-C power adapter. Prices start at about $1500 for a model with 32 GB of RAM, 256 GB of storage, and the non-touch display. I’m loading it up with apps as I write this, but I’m eager to get started. More soon. Paul Thurrott is an award-winning technology journalist and blogger with 30 years of industry experience and the author of 30 books. He is the owner of and the host of three tech podcasts: with Leo Laporte and Richard Campbell, , and with Brad Sams. He was formerly the senior technology analyst at Windows IT Pro and the creator of the SuperSite for Windows from 1999 to 2014 and the Major Domo of Thurrott.com while at BWW Media Group from 2015 to 2023. You can reach Paul via , or . Join the crowd where the love of tech is real - become a Thurrott Premium Member today! Sign up for our new free newsletter to get three time-saving tips each Friday
LOS ANGELES — Londynn Jones scored 15 points, making all five of her 3-pointers, and fifth-ranked UCLA stunned No. 1 South Carolina 77-62 on Sunday, ending the Gamecocks' overall 43-game winning streak and their run of 33 consecutive road victories. The Gamecocks (5-1) lost for the first time since April 2023, when Caitlin Clark and Iowa beat them in the NCAA Tournament national semifinals. Te-Hina Paopao scored 18 points and Tessa Johnson scored 14 for the Gamecocks, whose road winning streak was third-longest in Division I history. It was the first time UCLA took down a No. 1 team in school history, having been 0-20 in such games. The program's previous best wins were over a couple of No. 2s — Oregon in 2019 and Stanford in 2008. Elina Aarnisalo added 13 points as one of five Bruins in double figures. UCLA (5-0) dominated from start to finish, with the Bruins' suffocating defense preventing the Gamecocks from making any sustained scoring runs. South Carolina: The Gamecocks trailed by double-digits at halftime for the first time since Dec. 21, 2021, against Stanford, according to ESPN. Chloe Kitts, who averages a team-leading 14 points, finished the game with 2 points on 1 of 7 shooting. UCLA: The Bruins led 43-22 at halftime. Eight different players scored and contributed to 11-0 and 7-0 runs in the first and second quarters as they shot 52% from the field. The first quarter set the tone for a game in which the Gamecocks never led. They missed their first nine shots and were 4 of 18 from the floor in the quarter. UCLA ran off 11 straight points to take a 20-10 lead into the second quarter. The Bruins dominated the boards, 41-34, and held the Gamecocks well under their scoring average of 80.2 points. South Carolina travels to Florida to meet Iowa State in the Fort Myers Tipoff on Thanksgiving. UCLA travels to the Rainbow Wahine Showdown in Hawaii to play UT Martin on Friday. Get local news delivered to your inbox!
Audit initiates 100 complaints against Montana guides, outfittersChargesheet filed against Srinagar youth for ‘passing’ migrant Pandit employees’ data to handlers in Pakistan
Romanian Prime Minister Marcel Ciolacu looks likely to win the most votes in the first round of the presidential election, with the Black Sea state's staunch support for Ukraine possibly at stake in the second round. Login or signup to continue reading While exit polls on Sunday put Social Democrat Ciolacu, 56, comfortably ahead on 25 per cent, the identity of his opponent in the second-round runoff was uncertain. Centre-right candidate Elena Lasconi, 52, was on 18 per cent in exit polls, followed closely by two hard-right candidates, Calin Georgescu, 62, and George Simion, 38, on 16 per cent and 15 per cent respectively. Exit poll data does not capture the preferences of hundreds of thousands of Romanians who live and vote abroad. Simion, who opposes military aid to Ukraine, is particularly popular with diaspora voters. Romania's president has a semi-executive role that gives him or her control over defence spending - likely to be a difficult issue as Bucharest comes under pressure to uphold NATO spending goals during Donald Trump's second term as US president while trying to reduce a heavy fiscal deficit. Lasconi told supporters after exit polls were released that she was optimistic about making the runoff on December 8. "But as you can see, the results are very tight, let us wait until tomorrow's results to rejoice." Campaigning focused largely on the soaring cost of living, with Romania having the EU's biggest share of people at risk of poverty. Lasconi, a former journalist, joined the Save Romania Union (USR) in 2018 and became party head this year. She believes in raising defence spending and helping Ukraine, and surveys suggest she would beat Ciolacu in a runoff. But if Simion or Georgescu comes second, analysts say Lasconi is likely to urge her supporters to vote for Ciolacu to prevent a hard-right victory. Georgescu has made pro-Russian and anti-NATO comments. Australian Associated Press DAILY Today's top stories curated by our news team. Also includes evening update. WEEKDAYS Grab a quick bite of today's latest news from around the region and the nation. WEEKLY The latest news, results & expert analysis. WEEKDAYS Catch up on the news of the day and unwind with great reading for your evening. WEEKLY Get the editor's insights: what's happening & why it matters. WEEKLY Love footy? We've got all the action covered. WEEKLY Every Saturday and Tuesday, explore destinations deals, tips & travel writing to transport you around the globe. WEEKLY Get the latest property and development news here. WEEKLY Going out or staying in? Find out what's on. WEEKDAYS Sharp. Close to the ground. Digging deep. Your weekday morning newsletter on national affairs, politics and more. WEEKLY Follow the Newcastle Knights in the NRL? Don't miss your weekly Knights update. TWICE WEEKLY Your essential national news digest: all the big issues on Wednesday and great reading every Saturday. WEEKLY Get news, reviews and expert insights every Thursday from CarExpert, ACM's exclusive motoring partner. TWICE WEEKLY Get real, Australia! Let the ACM network's editors and journalists bring you news and views from all over. AS IT HAPPENS Be the first to know when news breaks. DAILY Your digital replica of Today's Paper. Ready to read from 5am! DAILY Test your skills with interactive crosswords, sudoku & trivia. Fresh daily!World-renowned health innovator will lead global collaboration and health equity work FLINT, Mich. , Dec. 16, 2024 /PRNewswire/ -- Insight Health System (Insight), a physician-led organization focused on excellence in health care and community well-being, has named Dr. Maliha Hashmi , a pioneer in the fields of AI-driven prevision care, health equity and wellness advocacy, as the organization's first Global Ambassador. "Dr. Hashmi's unparalleled reputation as a health leader and innovator around the world, combined with her dedication to underserved populations and her commitment to using technology for good, aligns perfectly with Insight's mission focused on providing care that is second to none through love and compassion," said Dr. Jawad Shah , founder and chief executive officer of Insight. "Her leadership will be invaluable in helping Insight shape the future of health care." As Global Ambassador, Dr. Hashmi will be intimately involved in a range of large-scale initiatives aimed at population health, health equity, value-based care and preventative care. She will play a critical role in ensuring that Insight hospitals remain leaders in global health care innovation and advancing patient-centered care while fostering sustainable growth and economic development within the communities they serve. Her strategic vision will ensure that Insight continues to deliver health equity and forward-thinking care for generations to come. Throughout her career, Dr. Hashmi has championed the humanization of technology, ensuring advancements in health care strengthen human connection, compassion and accessibility. Her innovative approach integrates smart systems designed to enhance efficiency, elevate patient care and improve health outcomes – all under the guiding principle of "health care for everyone, everywhere." Dr. Hashmi has earned numerous accolades, including recently being ranked first among the Top 10 Female Innovators and Leaders Globally by Entrepreneur Mirror, and one of the Top 50 Most Influential Muslims in America by EqualityX. She holds advanced degrees from Harvard and MIT and has served as a World Economic Forum Global Future Expert and V20 Delegate for G20. "I am deeply honored to take on this role as Global Ambassador for Insight," said Dr. Hashmi. "My goal is to champion health care for everyone, everywhere, supporting Insight's mission to refine processes, increase efficiency and deliver patient care second to none to communities across the globe. I am excited to drive innovation, compassion and excellence in patient care, making health care accessible and dignified for all." Insight, led by Dr. Jawad Shah , is committed to serving underserved communities through a multidisciplinary approach that balances cutting-edge medical technologies with compassionate patient care. Dr. Hashmi's appointment as Global Ambassador further solidifies Insight's mission to expand the boundaries of health care innovation and equitable service delivery. Follow along with the latest from Insight Health System on Facebook , Instagram , LinkedIn , TikTok and YouTube . Follow updates on Dr. Maliha Hashmi on the following platforms: LinkedIn: http://linkedin.com/in/dr-maliha-hashmi Instagram: https://www.instagram.com/malihahashmiofficial/ About Insight Health System Insight Health System is a physician-led organization focused on pioneering excellence in health care and community well-being. Our expertise is in transforming distressed hospitals into stable, patient-centric care that is second-to-none. With a track record for innovation in health care, research and development, Insight Health System provides the communities we serve with world-class health care services at the forefront of medical technology. Our network currently includes a portfolio of entities encompassing six acute care hospitals (three of which are nonprofit), six surgery centers, 28 clinics, 580 physicians, 10 unions and 4,200 employees. Collectively, Insight Health System hospitals provide nearly 100,000 patient days annually. View original content to download multimedia: https://www.prnewswire.com/news-releases/insight-health-system-appoints-dr-maliha-hashmi-as-global-ambassador-302332878.html SOURCE Insight Health System
Stockhead Don't miss out on the headlines from Stockhead. Followed categories will be added to My News. From artificial intelligence (A.I) to zygotes, the biotech sector this year delivered the A to Z of excitement, intrigue, occasional disappointment and downright disaster. His virtual stethoscope on hand, Dr Boreham was on duty to diagnose every announcement (OK – almost every pronouncement), ranging from genuine regulatory approvals and commercial deals, to brazen attempts to spinning out failed trails. The year started with deep pessimism but looks like ending with a powerful rally amid a flurry of trial results, approvals and – of course – capital raisings. So, here’s the towering year cut to alphabetic brevity: A is for AI, as in artificial intelligence, not artificial insemination. Only the bravest device and diagnostic plays don’t purport to be using the tool – but there’s a gaping chasm between real AI and tricked-up humanoid intelligence known as ‘algos’ (algorithms). Still, AI is radically automating surgical procedures. All the robots need to do is to perfect their golf swing and surgeons will be headed the way of facsimiles (still used in the pathology sector, by the way) and Sony Beta tapes. B is for goodbye to Biden and probably most of his healthcare reforms including the ambitious Moonshot cancer eradication program. B is for Bcal Diagnostics, which is on-track for a commercial launch of its blood-based breast cancer detection tool in early 2025. B is also for the baloney about pending big-ticket partnerships and regulatory approvals that never happen, multi-billion dollar ‘addressable markets’ and failed trials morphing into successful ones with data mining. C is for the culprits who know who they are. C is for ‘Cannabis corner’ which has generally disappointed, but a standout among the weeds is Neurotech International with its proposed cannabinoid-based treatment for childhood neurological disorders. C is also for a cascade of capital raisings. Many were small, admittedly, but Telix and Opthea blazed the way with raisings of $650 million and $220 million respectively. D is for Dimerix, a sector winner on the back of two distribution deals that had front-end cash. We await the results of the company’s phase III trial for the rare kidney disease focal segmental glomerulosclerosis (FSGS), due next year. D is also for depression, not a reference to the US Democrats but clinical work on the part of Actinogen (depression and Alzheimer’s), Trivarx (depression and sleep) and Avecho Biotechnology (pot). E is for Emvision, which hopes to start a pivotal trial for its portable stroke detection unit by March next year. F is for failure. In a year of soaring sectoral success, there are always casualties as well. The private point-of-care diagnostics house Ellume called in the receivers in June, reportedly owing $200 million to creditors. Genetic Technologies appointed voluntary administrators in November, after a capital raising fell well-short of the minimum $2 million required. In October, Patrys cancelled its lead DNA damage repair program, citing “manufacturing challenges” and in a rare setback, CSL axed its drug candidate for acute myocardial infarction? Missed its primary endpoint in an expansive – and expensive – trial. Oh, F ruitcake! G is for the great windfall for Neuren Pharmaceuticals, which last month pocketed $US50 million from a one-third share of an FDA rare paediatric disease priority review voucher, and a similar amount in royalties from Daybue (trofinetide) sales. G is also for Genetic Signatures, which won long-awaited FDA approval for its Easyscreen molecular test that detects eight gastro-intestinal parasites at once. H is for ‘hero’ stock Pro Medicus, now valued at $24 billion and worth more than the smallest of biotech’s former Big Three, Cochlear. So, make that the biotech Big Four. I is for IPOs (and lack thereof). Conditions remained subdued, but Blinklab (autism testing) joined the bourse in early April, breaking an eight-month drought, while Renerve (nerve repair) and Vitrafy (cryogenics) debuted last month. I is for drug repurposer Island Pharmaceuticals and its quest to rid the world of the rapidly spreading, mosquito borne dengue fever. I is also for immune-oncology house Immutep and Imugene and their steady stream of trial updates. The challenge is not to confuse the two companies and work out which trial is which, bearing in mind that neither has an approved therapy. J is for janus kinase (JAK) inhibitor, which delivered its inventors, Prof Andrew Wilks and Dr Chris Burns, the $250,000 Prime Minister’s Prize for Innovation. JAKs had their day in the sun when the FDA in late 2023 approved the locally developed JAK-based Ojjaara (momelotinib) for myelofibrosis. Ojjaara was invented by the head of Amplia Therapeutics, Dr Burns and founder of the formerly ASX-listed Cytopia, Prof Wilks. And Prime Minister Anthony Albanese awarded the prize in October this year. K is for Kamala – Kamala who? And Kiwi companies. The latter are key contributors to the ASX biotech sector, via the likes of Aroa Biosurgery and cervical cancer screener Truscreen, Pacific Edge and the overlooked Resmed rival Fisher & Paykel Health. Neuren also had NZ roots, while breast imager Volpara was taken over and delisted in May. L is for leadership changes at more than a dozen companies, with a high female representation among incoming CEOs. At Genetic Signatures, Allison Rossiter succeeded Dr John Melki. At Impedimed, Dr Parmjot Bains took over from Richard Valencia. At Somnomed, Karen Borg took over from Neil Verdal-Austin At Chimeric Therapeutics, Jennifer Chow suddenly departed in favor of Dr Rebecca McQualter, while at Starpharma Cheryl Maley took over from Dr Jackie Fairley. Going against the trend, at Opthea the US-based Dr Fred Guerard replaced founder Dr Megan Baldwin. At Cann Group, Peter Koetsier took over from Jenni Pilcher. On April 23, Pharmaust (now Neurizon) announced the departure of CEO Dr Michael Thurn and his re-appointment on May 31 – surely the shortest resignation in biotech history. At Vitura Health, Geoff Cockerill replaced Rodney Cocks, which poses the question: who will be responsible for the cock-ups? M is for Making America Healthy Again by vilifying vaccines and established medical science. M is also for stem cell developer Mesoblast, which has regained investor favour on expectations it will finally, finally win FDA approval (for paediatric graft-versus-host disease). D (decision) day is expected on or before January 7 next year. N is for name change, with Pharmaust becoming Neurizon, Cronos Australia morphing into Vitura Health and Regeneus regenerating into Cambium Bio. MGC Pharmaceuticals became Argent Biopharma and LBT Innovations is now Clever Culture Systems. Are the marketing moniker gurus wasting their time? As James Garner, the head of Percheron (formerly Antisense Therapeutics) remarked: “You could call it Potato Therapeutics and it would just be the same.” N is also for Nasdaq, with Telix and Radiopharm pursuing secondary listings on the tech-heavy exchange. Late last year, Incannex Healthcare redomiciled to the Nasdaq and heart valve innovator Anteris Technologies has just done so. O is for the semaglutide injectable obesity drugs, best known as the branded Ozempic. Their emergence has prompted speculation about reduced need for sleep apnoea aids (sorry, Resmed) and dialysis (sorry, CSL). Is it really the end of what TV reporters breathlessly describe as ‘obesity epidemic’? We say F , as in Fat Chance. O is also for Opthea, which has two extensive phase III trials for wet AMD, a leading cause of blindness. We’ll ‘see’ next year when the first results are out. They will be company making – or company breaking. P is for the towering Pro Medicus, which continues to blitz the US radiology market within both ‘sandstone’ institutions and the private hospitals. P is also for psychedelic therapies and the fortunes of dabblers Bioxyne, Tryptamine Therapeutics, Emyria and – on the periphery – Little Green Pharma. The FDA is far from convinced – but new health czar Robert F Kennedy Junior is an ardent fan and any bureaucrat troubled by the science can either tune in or drop out. Q is for ‘quite impressive’, as in the sector’s outperformance relative to the broader market. Q is also for ‘quality’ which sums up most of Australia’s medical research. Q also stands for ‘quixotic’, as in RFK Jr. R is for Raygun, our break-dancing Olympian who made failure our biggest national attribute since Gallipoli. R is for radiotherapies and diagnostics. The rise and rise of Telix is well documented, but Clarity Pharmaceuticals and Radiopharm have also emerged from the doldrums. S is for share success. Companies chalking impressive share gains this year include the come-from-nowhere Invion, Clarity, Mesoblast, Polynovo, Actinogen, Genetic Signatures, Syntara and Immutep. S is also for the slow-burn success of SDI, a supplier and exporter of dental consumables (notably filling materials) since 1972. T is for Telix and Trump. But they’ve both had more than their fair share of airtime so we will give a mention to Truscreen – the only company we know that is targeting non-developed countries for its cervical cancer screening tool. U is for unusual, a trait we would ascribe to Opyl’s algorithmic tool that claims to predict the likelihood of a clinical trial succeeding. The company will start the ‘world’s first’ biotech fund run by AI, so we will soon see how this brave new world pans out. V is for vaccines. We’re going to be hearing a lot more about the V-word in the world of RFK Junior. Fortunately, his anti-vaccination stance is unlikely to affect any ASX-listed biotechs, apart from CSL at the periphery. V is also for the US veterans’ market, a healthcare system that rivals the size of Australia’s. The sector is being targeted by lung imaging plays 4D Medical, Cyclopharm and Singular Health. W is for the buzzing wound care space: Polynovo, Avita and the aforementioned Aroa are encroaching the US market one dressing at a time, although Next Science appears to have been left behind. X is for (e)xiting companies: Volpara and Ellume aside, Rhinomed went private and Visioneering plans to do the same, while Allegra Medical Technologies was taken over by an entity associated with a director. Argent Biopharma sought better fortunes on the London exchange but decided to stay here. X is also for (e)xaggerated claims about the size of an addressable market and the scope of a new product to disrupt well-established technologies. Y is for “yes” from the FDA for Botanix and its treatment for excessive sweating – a case of persistence and perspiration. It was also “yes” for Echo IQ and its aortic stenosis detection diagnostic which is – you’ve got it - AI based. The agency also approved Orthocell’s nerve repair cuff, Remplir while LTR Pharma is on the up-and-up after winning local consent for its Spontan erectile dysfunction nasal spray. Z is also for zygote, “a diploid cell formed by the fusion of two haploid gametes during fertilisation in eukaryotic organisms with sexual reproduction”. Our coverage admittedly was zygote-free but if you haven’t heard at least one new biotech term a year, it’s been a wasted 12 months. Z is for Zoo (see ‘Trump Administration’). Z is also for zzzz and the quest to put the insomnia endemic (that word again) to bed once and for all. The long-standing Compumedics has an increasingly snazzy array of sleep diagnostic gizmos. Trivarx is exploring the link between bad sleep and depression. Meanwhile, Avecho is running a phase III trial to prove that cannabinoids may cause drowsiness ... who would have thought? Speaking of rest, Dr Boreham’s Crucible is taking one. Jab another vial of Ozempic for a guilt-free festive season and have a great one. This column first appeared in Biotech Daily Originally published as Crucible: Dr Boreham’s A-To-Z of 2024 biotech More related stories Stockhead Can Adore Beauty’s new CEO turn it around? Adore Beauty faces growth challenges but new CEO Sacha Laing is aiminf for a 30pc revenue boost and tripling of margins in three years. Read more Stockhead Lithium stocking stuffers Stockhead has stuffed a collection of ASX lithium companies with plenty of exploration upside into a stocking for you. Read more蒲隆地記者穆霍扎因在私人WhatsApp群組中分享訊息,面臨12年監禁的風險。(取自RSF官網) ◎陳成良 A journalist in Burundi is at risk of a 12-year jail term over information she shared in a private WhatsApp group, global media watchdog Reporters Without Borders said. 全球媒體監督組織「無國界記者組織」表示,蒲隆地1名記者因在私人WhatsApp群組中分享訊息,面臨12年監禁的風險。 請繼續往下閱讀... It described the possible sentence sought by prosecutors against Sandra Muhoza, who has already been detained for more than seven months, "beyond comprehension" and "unspeakably harsh and unfair". 該組織將檢察官針對桑德拉‧穆霍扎提出的可能的判決,描述為「令人難以理解」和「殘酷不公」,穆霍扎已被拘留7個多月。 Muhoza is accused of "undermining the integrity of the national territory" and "ethnic aversion", according to the media rights group, which is known by its French acronym RSF. 據該媒體權利組織(其法語縮寫為RSF)稱,穆霍扎被指控犯有「破壞國家領土完整」和「種族仇恨」罪。 The prosecution made a request at a High Court hearing in Bujumbura on November 12 for a total prison sentence of 12 years for the two charges as well as a fine of one million Burundian francs ($336), RSF said. RSF表示,檢方在11月12日布瓊布拉高等法院的聽證會上,要求對這2項指控判處共12年監禁,並處以100萬蒲隆地法郎(336美元)罰款。 beyond comprehension:形容詞片語,無法理解;難以置信;超出理解範圍。例句:The speed at which technology is advancing is sometimes beyond comprehension.(科技進步的速度有時令人難以置信。) aversion:名詞,強烈的嫌惡或反感。例句:Many people have an aversion to violence.(許多人對暴力深惡痛絕。) 不用抽 不用搶 現在用APP看新聞 保證天天中獎 點我下載APP 按我看活動辦法
An increase in roadside drug testing is being urged after NSW fell well short its own targets, despite a spike in drug-related driving deaths. or signup to continue reading A report from motoring body NRMA found one-in-10 NSW drivers who undertook a roadside drug test delivered a positive result, as the state carried out 160,000 tests in 2023. That is well below the government's target of 200,000 test per year. A total of 79 people died in drug-related crashes in 2023, up from 55 in 2022. NRMA spokesman Peter Khoury said a lift in random drug testing was urgently needed. "It is extremely alarming that one-in-10 drivers pulled over for a random drug test on the side of the road tested positive at the same time that we are seeing a huge spike in deaths - jumping 44 per cent in one year," he said. "Too many Australians are driving high and it's clear we need to ramp up enforcement and to boost education campaigns around ending this dangerous behaviour." The found cannabis was the drug used in 70 per cent of drug-related crashes, beating out methylamphetamine (43 per cent) and cocaine (seven per cent). A whopping 85 per cent of drivers involved in fatal, drug-related crashes were males. Along with hitting the target of 200,000 roadside drug tests by 2026, the NRMA wants police to be given more resources to have stronger visibility on the road. It also called for better public education about the dangers of drug-driving. In October, a NSW Bureau of Crime Statistics and Research report questioned the deterrent effect of the roadside drug testing scheme because a spike in charges was not matched with an increase to the proportion of positive tests. More than 13,800 drug driving offences were recorded across NSW in 2023, up a staggering 836 per cent from the 1409 logged in 2014. However, only 39,000 tests were performed in 2014, a tally that had grown to 156,000 by 2023. The bureau found no evidence the increase was driven by a change in drug use or driving behaviour. DAILY Today's top stories curated by our news team. WEEKDAYS Grab a quick bite of today's latest news from around the region and the nation. WEEKLY The latest news, results & expert analysis. WEEKDAYS Catch up on the news of the day and unwind with great reading for your evening. WEEKLY Get the editor's insights: what's happening & why it matters. WEEKLY Love footy? We've got all the action covered. WEEKLY Every Saturday and Tuesday, explore destinations deals, tips & travel writing to transport you around the globe. WEEKLY Going out or staying in? Find out what's on. WEEKDAYS Sharp. Close to the ground. Digging deep. Your weekday morning newsletter on national affairs, politics and more. TWICE WEEKLY Your essential national news digest: all the big issues on Wednesday and great reading every Saturday. WEEKLY Get news, reviews and expert insights every Thursday from CarExpert, ACM's exclusive motoring partner. TWICE WEEKLY Get real, Australia! Let the ACM network's editors and journalists bring you news and views from all over. AS IT HAPPENS Be the first to know when news breaks. DAILY Your digital replica of Today's Paper. Ready to read from 5am! DAILY Test your skills with interactive crosswords, sudoku & trivia. Fresh daily! Advertisement AdvertisementArguments over whether Luigi Mangione is a 'hero' offer glimpse into unusual American momentBIRMINGHAM, Ala. , Dec. 16, 2024 /PRNewswire/ -- RxBenefits, Inc., the employee benefits industry's first technology-enabled pharmacy benefits optimizer (PBO), announced today that Robert Gamble has been appointed Chief Executive Officer, effective immediately. Gamble succeeds Wendy Barnes , who has decided to pursue another professional opportunity. Gamble has also joined the RxBenefits Board of Directors. Gamble , a seasoned leader with more than 20 years of experience in the healthcare and pharmacy benefits industry, has been an integral part of RxBenefits' executive leadership team for the past nine years. Most recently, he served as President and Chief Operating Officer (COO). As COO, Gamble led the strategy, technology, operations, and account management functions during a period of significant expansion and growth for the company, including launching new products and entering new market segments. Gamble previously held the position of Chief Financial Officer. "I am proud to take the helm of a company whose sole mission is to be a trusted partner to our clients and transparently deliver pharmacy benefits aligned to their unique goals," Gamble said. "We have a strong leadership team, and more than 1,200 employees focused on helping our clients achieve sustainable savings while delivering robust pharmacy benefits to their members." "Over nearly a decade, Robert has proven his strong ability to drive growth as he has helped scale RxBenefits into the pre-eminent and first technology-enabled pharmacy benefits optimizer," said Mark Taber , a Managing Director at Great Hill Partners and member of the RxBenefits Board of Directors. "We are confident that he is the right choice to lead RxBenefits forward, leveraging his deep, nuanced understanding of the industry and company to deliver greater value to clients nationwide." "We're appreciative of Wendy's commitment to the company as well as her efforts to maintain RxBenefits' status as a leading provider of cost-effective pharmacy benefits solutions and exceptional service to clients," said John Maldonado , Managing Partner at Advent International and RxBenefits board member. "We're excited for Robert to take on his new role and believe he is well-positioned to lead the RxBenefits team and propel the company to its next phase of growth." "I am grateful for Wendy's leadership over the last two years. She accelerated our momentum and prepared us for our next phase of expansion," Gamble added. "We had a strong earnings year in 2024, continuing our track record of robust financial performance. We also have an ambitious strategic plan for 2025 and beyond. I look forward to what we will achieve and how we will increasingly help our clients contain soaring pharmacy benefits costs while taking great care of their members." RxBenefits continues to grow and innovate to meet its clients' emerging needs for cost-effective pharmacy benefits solutions, adding 500 employees just since 2022 while continuing to deliver industry-leading, award-winning customer and member service. About RxBenefits RxBenefits is the nation's first and leading technology-enabled pharmacy benefits optimizer (PBO) with more than 1,200 pharmacy pricing, data, and clinical experts working together to deliver prescription benefit savings to employee benefits advisors and their self-insured clients. Serving more than 3 million members , RxBenefits brings market-leading purchasing power, independent clinical solutions, and high-touch service to its customers – ensuring that all plan sponsors, regardless of size, can provide an affordable and valuable pharmacy benefits plan to their employees. The company is headquartered in Birmingham, Alabama . View original content to download multimedia: https://www.prnewswire.com/news-releases/rxbenefits-inc-appoints-robert-gamble-chief-executive-officer-302332862.html SOURCE RxBenefits
NEW YORK , Nov. 21, 2024 /PRNewswire/ -- S&P Global Market Intelligence has released a report today highlighting the convergence in public and private credit markets. The newly published Public and Private Markets Outlook: Converging on Credit is part of S&P Global Market Intelligence's Big Picture 2025 Outlook Report Series. In this new report, S&P Global Market Intelligence's capital markets analysts highlight how public and private credit markets have become increasingly intertwined in 2024, and why we expect this trend to continue in 2025. Public debt markets have grown, but not at the expense of the $1.5 trillion private markets, which continue their rapid expansion. " It may be no coincidence that the fall in Credit Default Swap (CDS) credit events aligns with the growth in provision of private credit. Many companies now have recourse to lines of credit from private sources to an extent not seen in previous cycles. This trend is likely to continue in 2025 but may raise questions about the transparency and measurement of credit risk in private credit funds, where the exposure is ultimately shifted," said Gavan Nolan , Executive Director at S&P Global Market Intelligence. Key highlights from the report include: The $1.5 trillion global private market continues to see new activity as banks seek out new partnerships. Meanwhile, fund managers are trying to enter public markets through new investment vehicles. Credit events in the CDS market have stayed low, with just two credit event auctions — the settlement mechanism for CDS — in 2024. This is the fourth consecutive year that auctions have not exceeded three annually and brings the 3-year moving average down to the lowest levels not seen since the credit bubble before the global financial crisis in 2007-2008. With the size of the private credit market approaching $2 trillion , some regulators and investors are calling for more rules and transparency in the largely unregulated space. The private credit market, meanwhile, is only growing, with some estimates calling for total assets under management to more than double by 2028. To request a copy of Public and Private Markets Outlook: Converging on Credit , please contact [email protected] . S&P Global Market Intelligence's opinions, quotes, and credit-related and other analyses are statements of opinion as of the date they are expressed and not statements of fact or recommendation to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. About S&P Global Market Intelligence At S&P Global Market Intelligence, we understand the importance of accurate, deep and insightful information. Our team of experts delivers unrivaled insights and leading data and technology solutions, partnering with customers to expand their perspective, operate with confidence, and make decisions with conviction. S&P Global Market Intelligence is a division of S&P Global (NYSE: SPGI ). S&P Global is the world's foremost provider of credit ratings, benchmarks, analytics and workflow solutions in the global capital, commodity and automotive markets. With every one of our offerings, we help many of the world's leading organizations navigate the economic landscape so they can plan for tomorrow, today. For more information, visit www.spglobal.com/marketintelligence . Media Contact Amanda Oey S&P Global Market Intelligence +1 212-438-1904 [email protected] or [email protected] SOURCE S&P Global Market Intelligence
After Trump's Project 2025 denials, he is tapping its authors and influencers for key roles